Niklas Loman
Niklas Loman
Associate Professor Dept of Oncology Lund University Hospital
Verified email at med.lu.se
Title
Cited by
Cited by
Year
Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies
A Antoniou, PDP Pharoah, S Narod, HA Risch, JE Eyfjord, JL Hopper, ...
The American Journal of Human Genetics 72 (5), 1117-1130, 2003
39232003
Gene-expression profiles in hereditary breast cancer
I Hedenfalk, D Duggan, Y Chen, M Radmacher, M Bittner, R Simon, ...
New England Journal of Medicine 344 (8), 539-548, 2001
20182001
Oral poly (ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial
A Tutt, M Robson, JE Garber, SM Domchek, MW Audeh, JN Weitzel, ...
The Lancet 376 (9737), 235-244, 2010
18342010
Oral poly (ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial
MW Audeh, J Carmichael, RT Penson, M Friedlander, B Powell, ...
The Lancet 376 (9737), 245-251, 2010
13722010
Olaparib Monotherapy in Patients With Advanced Cancer and a Germline BRCA1/2 Mutation
B Kaufman, R Shapira-Frommer, RK Schmutzler, MW Audeh, ...
Journal of clinical oncology 33 (3), 244-250, 2014
12822014
A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor–negative breast cancer in the general …
AC Antoniou, X Wang, ZS Fredericksen, L McGuffog, R Tarrell, ...
Nature genetics 42 (10), 885, 2010
3702010
Family history of breast and ovarian cancers and BRCA1 and BRCA2 mutations in a population-based series of early-onset breast cancer
N Loman, O Johannsson, U Kristoffersson, H Olsson, A Borg
Journal of the National Cancer Institute 93 (16), 1215-1223, 2001
3362001
Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial
M Martin, FA Holmes, B Ejlertsen, S Delaloge, B Moy, H Iwata, ...
The Lancet Oncology 18 (12), 1688-1700, 2017
3242017
Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer
TR Rebbeck, N Mitra, F Wan, OM Sinilnikova, S Healey, L McGuffog, ...
Jama 313 (13), 1347-1361, 2015
3222015
Genome-wide association study in BRCA1 mutation carriers identifies novel loci associated with breast and ovarian cancer risk
FJ Couch, X Wang, L McGuffog, A Lee, C Olswold, KB Kuchenbaecker, ...
PLoS genetics 9 (3), e1003212, 2013
2822013
Molecular classification of familial non-BRCA1/BRCA2 breast cancer
I Hedenfalk, M Ringnér, A Ben-Dor, Z Yakhini, Y Chen, G Chebil, R Ach, ...
Proceedings of the National Academy of Sciences 100 (5), 2532-2537, 2003
2352003
Cytokeratin 5/14-positive breast cancer: true basal phenotype confined to BRCA1 tumors
M Laakso, N Loman, Ĺ Borg, J Isola
Modern pathology 18 (10), 1321, 2005
2322005
Genomic subtypes of breast cancer identified by array-comparative genomic hybridization display distinct molecular and clinical characteristics
G Jönsson, J Staaf, J Vallon-Christersson, M Ringnér, K Holm, C Hegardt, ...
Breast Cancer Research 12 (3), R42, 2010
2062010
Steroid receptors in hereditary breast carcinomas associated with BRCA1 or BRCA2 mutations or unknown susceptibility genes
N Loman, O Johannsson, PO Bendahl, Ĺ Borg, M Fernö, H Olsson
Cancer 83 (2), 310-319, 1998
2061998
Moderate frequency of BRCA1 and BRCA2 germ-line mutations in Scandinavian familial breast cancer.
S Hĺkansson, O Johannsson, U Johansson, G Sellberg, N Loman, ...
American journal of human genetics 60 (5), 1068, 1997
2051997
Identification of new microRNAs in paired normal and tumor breast tissue suggests a dual role for the ERBB2/Her2 gene
H Persson, A Kvist, N Rego, J Staaf, J Vallon-Christersson, L Luts, ...
Cancer research 71 (1), 78-86, 2011
1882011
Identification of subtypes in human epidermal growth factor receptor 2–positive breast cancer reveals a gene signature prognostic of outcome
J Staaf, M Ringnér, J Vallon-Christersson, G Jönsson, PO Bendahl, ...
Journal of Clinical Oncology 28 (11), 1813-1820, 2010
1842010
Functional analysis of BRCA1 C-terminal missense mutations identified in breast and ovarian cancer families
J Vallon-Christersson, C Cayanan, K Haraldsson, N Loman, ...
Human molecular genetics 10 (4), 353-360, 2001
1792001
Efficacy and safety of olaparib monotherapy in germline BRCA1/2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapy
SM Domchek, C Aghajanian, R Shapira-Frommer, RK Schmutzler, ...
Gynecologic oncology 140 (2), 199-203, 2016
1712016
BRCA2 germ-line mutations are frequent in male breast cancer patients without a family history of the disease
K Haraldsson, N Loman, QX Zhang, O Johannsson, H Olsson, Ĺ Borg
Cancer research 58 (7), 1367-1371, 1998
1691998
The system can't perform the operation now. Try again later.
Articles 1–20